Literature DB >> 35242680

Risk factors and prognostic index model for pancreatic cancer.

Hui Huang1, Jichun Sun1, Zheming Jiang2, Xianlin Zhang3, Zheng Li3, Hongwei Zhu1, Xiao Yu1.   

Abstract

BACKGROUND: Pancreatic cancer is a highly malignant tumor with poor prognosis. Chronic inflammation contributes to the progression of pancreatic cancer. However, few studies have examined the prognostic role of inflammatory markers in this cancer. Our study sought to analyze the prognostic risk factors of and construct a prognostic index (PI) model using inflammatory markers for pancreatic cancer.
METHODS: Forty-eight patients diagnosed with pancreatic cancer at our hospital were selected for this retrospective analysis. Data on the general clinical characteristics, tumor-related features, blood index factors, and treatment methods were collected. The Cox proportional-hazards model was used to analyze the factors affecting the prognosis, and the Kaplan-Meier analysis was used to draw the survival curve.
RESULTS: The median overall survival time was 14.5 months, and the 1-, 2-, and 3-year survival rates were 20.83% (10/48), 6.25% (3/48), and 4.17% (2/48), respectively. The univariate analysis showed that tumor grade, vascular invasion, adjacent tissue invasion, lymph node metastasis, tumor-node-metastasis (TNM) stage, the neutrophil-lymphocyte ratio (NLR), the platelet-lymphocyte ratio (PLR), and the lymphocyte-monocyte ratio (LMR) were significantly correlated with the median survival of pancreatic cancer patients (P<0.05). The Cox regression equation showed that tumor grade III-IV (X1), vascular invasion (X2), TNM stage III-IV (X3), a NLR >3.8 (X4), and a PLR >182.1 (X5) were independent risk factors affecting the prognosis of patients with pancreatic cancer (all P<0.05). The prognostic model for pancreatic cancer can be expressed as: PI =3.521X1+4.157X2+1.282X3+2.441X4+6.015X5. Patients with tumor grade I-II, non-vascular invasion, TNM stage I-II, a NLR ≤3.8, and a PLR ≤182.1 exhibited a higher 1-year survival rate. The areas under the receiver operating characteristic (ROC) curves for the NLR >3.8 and the PLR >182.1 were 0.778 and 0.713, respectively.
CONCLUSIONS: Tumor grade, vascular invasion, TNM staging, the NLR, and the PLR are independent risk factors affecting the prognosis of pancreatic cancer patients. The NLR and PLR have good clinical value in predicting the survival outcomes of pancreatic cancer patients. 2022 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Pancreatic cancer; prognosis; prognostic index model (PI model); risk factors

Year:  2022        PMID: 35242680      PMCID: PMC8825503          DOI: 10.21037/gs-21-848

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  28 in total

1.  Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, neutrophil-platelet score and prognostic nutritional index: do they have prognostic significance in metastatic pancreas cancer?

Authors:  Mutlu Dogan; Efnan Algin; Zeynep Tugba Guven; Meltem Baykara; Tugba Fahriye Kos; Oznur Bal; Nurullah Zengin
Journal:  Curr Med Res Opin       Date:  2017-12-15       Impact factor: 2.580

2.  Predictors of Early Mortality After Surgical Resection of Pancreatic Adenocarcinoma in the Era of Neoadjuvant Treatment.

Authors:  Ryan D Nipp; Andrea Zanconato; Hui Zheng; Cristina R Ferrone; Keith D Lillemoe; Jennifer Y Wo; Theodore S Hong; Jeffrey W Clark; David P Ryan; Carlos Fernández-Del Castillo
Journal:  Pancreas       Date:  2017-02       Impact factor: 3.327

3.  Short-term outcomes after vascular resection for pancreatic tumors: Lessons learned from 72 cases from a single Brazilian Cancer Center.

Authors:  Silvio Melo Torres; Diego Greatti Vaz da Silva; Héber S C Ribeiro; Alessandro L Diniz; Matheus Melo Lobo; André Luís de Godoy; Igor Correia de Farias; Wilson L da Costa; Victor Hugo F de Jesus; Felipe J F Coimbra
Journal:  J Surg Oncol       Date:  2019-12-06       Impact factor: 3.454

4.  Prognostic Impact of the Neutrophil-to-Lymphocyte Ratio in Borderline Resectable Pancreatic Ductal Adenocarcinoma Treated with Neoadjuvant Chemoradiotherapy Followed by Surgical Resection.

Authors:  Hirokazu Kubo; Takashi Murakami; Ryusei Matsuyama; Yasuhiro Yabushita; Nobuhiro Tsuchiya; Yu Sawada; Yuki Homma; Takafumi Kumamoto; Itaru Endo
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

5.  Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study.

Authors:  S R Bramhall; W H Allum; A G Jones; A Allwood; C Cummins; J P Neoptolemos
Journal:  Br J Surg       Date:  1995-01       Impact factor: 6.939

6.  Integrated Analysis of Long Non-Coding RNA and mRNA Expression Profile in Pancreatic Cancer Derived Exosomes Treated Dendritic Cells by Microarray Analysis.

Authors:  Jionghuang Chen; Shaowen Wang; Shengnan Jia; Guoping Ding; Guixing Jiang; Liping Cao
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

7.  Prognostic significance of blood inflammatory biomarkers NLR, PLR, and LMR in cancer-A protocol for systematic review and meta-analysis.

Authors:  Chellan Kumarasamy; Shanthi Sabarimurugan; Royam Madhav Madurantakam; Kartik Lakhotiya; Suja Samiappan; Siddhratha Baxi; Ramesh Nachimuthu; Kodiveri Muthukaliannan Gothandam; Rama Jayaraj
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

8.  The relation between inflammation-based parameters and survival in metastatic pancreatic cancer.

Authors:  Sema Turker; Ebru Cilbir; Deniz Can Guven; Cengiz Karacin; Suayib Yalcin
Journal:  J Cancer Res Ther       Date:  2021 Apr-Jun       Impact factor: 1.805

Review 9.  Inflammation and cancer.

Authors:  Mariko Murata
Journal:  Environ Health Prev Med       Date:  2018-10-20       Impact factor: 3.674

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.